Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04058028 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
A Phase 2 study of Systemic Lupus Erythematosus (SLE), sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
- 20
- Study locations
NCT04058028 is a Phase 2 study of Systemic Lupus Erythematosus (SLE) that has completed, run by Amgen. The registered enrollment target is 244 participants, below the 1,047-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04058028, a Phase 2 study of Systemic Lupus Erythematosus (SLE), has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care therapies.
Conditions Studied
Interventions
- DRUG Rozibafusp Alfa
- DRUG Placebo for Rozibafusp Alfa
Study Locations (20)
California
- Medvin Clinical Research - Covina
- Southern California Permanente Medical Group - Fontana
- University of California San Diego - La Jolla
- University of California Los Angeles - Los Angeles
- Stanford University Hospitals and Clinics - Palo Alto
- TriWest Research Associates - San Diego
Florida
- Centre for Rheumatology Immunology and Arthritis - Fort Lauderdale
- University of Florida - Gainesville
- Lakes Research LLC - Miami Lakes
- Heuer Medical Doctor Research LLC - Orlando
- Southwest Florida Clinical Research Center - Tampa
- AdventHealth Medical Group - Tampa
Georgia
- Piedmont Atlanta Hospital - Atlanta
- The Emory Clinic - Atlanta
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Imaging Endpoints - Scottsdale
Colorado
- University of Colorado Denver - Aurora
Connecticut
- Yale University - New Haven
Illinois
- Clinic of Robert Hozman, MD - Clinical Investigational Specialists, Inc - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04058028
The ClinicalTrials.gov registry entry for NCT04058028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,047-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (77% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 2 interventions - of which Rozibafusp Alfa is the first listed.
NCT04058028 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04058028 about?
NCT04058028 is a clinical study titled "Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)". The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care therapies.
What is the current status of trial NCT04058028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2020-02-19. Estimated completion is 2023-07-25.
What conditions does trial NCT04058028 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE).
What interventions are being tested in trial NCT04058028?
The interventions under investigation include: Rozibafusp Alfa (DRUG), Placebo for Rozibafusp Alfa (DRUG).
Who is sponsoring clinical trial NCT04058028?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04058028 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus (SLE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Descartes-08 for Patients With Systemic Lupus Erythematosus
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
COMPLETED · Phase 2
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
RECRUITING
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
RECRUITING · Phase 1
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.